The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome
作者： Amanda McBride , Sarah Houtmann , Lindsay Wilde , Carlos Vigil , Christine M. Eischen
关键词:
摘要: Avoidance of apoptosis is a key mechanism that malignancies, including acute leukemias and MDS, utilize in order to proliferate resist chemotherapy. Recently, venetoclax, an inhibitor the anti-apoptotic protein BCL-2, has been approved for treatment upfront AML unfit, elderly population. This paper reviews pre-clinical clinical data inhibitors currently development AML, ALL, MDS.
frontiersin.org
jefferson.edu
sci-hub.se 参考文章(69)
Yumi Matsuzaki, Kei-ichi Nakayama, Keiko Nakayama, Takashi Tomita, Miu Isoda, Dennis Y. Loh, Hiromitsu Nakauchi, Role of bcl-2 in the Development of Lymphoid Cells From the Hematopoietic Stem Cell Blood. ,vol. 89, pp. 853- 862 ,(1997) , 10.1182/BLOOD.V89.3.853
Ram6n Merino, Liyun Ding, Deborah J Veis, Stanley J Korsmeyer, Gabriel Nuñez, Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. The EMBO Journal. ,vol. 13, pp. 683- 691 ,(1994) , 10.1002/J.1460-2075.1994.TB06307.X
Laurence A. Turka, Gabriel Nuñez, Liyun Ding, Jeanne Gratiot-Deans, bcl-2 proto-oncogene expression during human T cell development. Evidence for biphasic regulation. Journal of Immunology. ,vol. 151, pp. 83- 91 ,(1993)
Shankar Varadarajan, Paramasivan Poornima, Mateus Milani, Krishne Gowda, Shantu Amin, Hong-Gang Wang, Gerald M. Cohen, Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner Oncotarget. ,vol. 6, pp. 12668- 12681 ,(2015) , 10.18632/ONCOTARGET.3706
A R D Delbridge, A Strasser, The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death & Differentiation. ,vol. 22, pp. 1071- 1080 ,(2015) , 10.1038/CDD.2015.50
K L B Knorr, P A Schneider, X W Meng, H Dai, B D Smith, A D Hess, J E Karp, S H Kaufmann, MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors Cell Death & Differentiation. ,vol. 22, pp. 2133- 2142 ,(2015) , 10.1038/CDD.2015.74
S Jilg, V Reidel, C Müller-Thomas, J König, J Schauwecker, U Höckendorf, C Huberle, O Gorka, B Schmidt, R Burgkart, J Ruland, HJ Kolb, C Peschel, RAJ Oostendorp, KS Götze, PJ Jost, None, Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients. Leukemia. ,vol. 30, pp. 112- 123 ,(2016) , 10.1038/LEU.2015.179
DJ Veis, Ch L Sentman, EA Bach, SJ Korsmeyer, None, Expression of the Bcl-2 protein in murine and human thymocytes and in peripheral T lymphocytes. Journal of Immunology. ,vol. 151, pp. 2546- 2554 ,(1993)
T M Kohl, C Hellinger, F Ahmed, C Buske, W Hiddemann, S K Bohlander, K Spiekermann, BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts Leukemia. ,vol. 21, pp. 1763- 1772 ,(2007) , 10.1038/SJ.LEU.2404776
Cheol-Min Park, Milan Bruncko, Jessica Adickes, Joy Bauch, Hong Ding, Aaron Kunzer, Kennan C. Marsh, Paul Nimmer, Alexander R. Shoemaker, Xiaohong Song, Stephen K. Tahir, Christin Tse, Xilu Wang, Michael D. Wendt, Xiufen Yang, Haichao Zhang, Stephen W. Fesik, Saul H. Rosenberg, Steven W. Elmore, Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. Journal of Medicinal Chemistry. ,vol. 51, pp. 6902- 6915 ,(2008) , 10.1021/JM800669S